[Dual diagnosis: depression and alcohol use disorder]

Area of Science:

• Psychiatry
• Addiction Medicine
• Pharmacology

Background:

• Depression and alcohol use disorder (AUD) frequently present as a dual diagnosis.
• The comorbidity is more common than chance, suggesting synergistic effects that complicate prognosis.
• Effective treatment requires addressing both conditions concurrently.

Purpose of the Study:

• To review treatment protocols for comorbid depression and AUD.
• To highlight the role of antidepressants, particularly SSRIs, in managing this dual diagnosis.
• To discuss the specific advantages of fluvoxamine in this patient population.

Main Methods:

• Literature review of treatment strategies for depression with comorbid AUD.
• Analysis of the efficacy of selective serotonin reuptuptake inhibitors (SSRIs).
• Evaluation of fluvoxamine's comparative benefits in treating comorbid depression and AUD.

Main Results:

• Treatment often involves antidepressants, AUD-specific medications, and psychotherapy.
• SSRIs are first-line antidepressants for this comorbidity.
• Fluvoxamine demonstrates specific advantages over other SSRIs for patients with depression and AUD.

Conclusions:

• Managing comorbid depression and AUD requires integrated treatment approaches.
• SSRIs are a key component of pharmacotherapy for this dual diagnosis.
• Fluvoxamine presents a potentially advantageous option for treating patients with both depression and AUD.